Latest Period
Q4 2025
Security Snapshot
Repare Therapeutics Inc. - Common shares, no par value (RPTX) Institutional Ownership
CUSIP: 760273102
13F Institutional Holders and Ownership History from Q1 2019 to Q1 2026
Institutions Reporting
45
Shares (Excl. Options)
25,162,567
Price
$2.60
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common shares, no par value
- Symbol
- RPTX
- Shares outstanding
- 42,837,925
- Price per share
- $2.59
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 25,162,567
- Total reported value
- $65,418,419
- % of total 13F portfolios
- 0%
- Share change
- -988,874
- Value change
- +$649,419
- Number of holders
- 45
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- RPTX - Repare Therapeutics Inc. - Common shares, no par value is tracked under CUSIP 760273102.
- 45 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 45 to 0 between Q4 2025 and Q1 2026.
- Reported value moved from $65,418,419 to $0.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 45 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 760273102?
CUSIP 760273102 identifies RPTX - Repare Therapeutics Inc. - Common shares, no par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 760273102:
Significant Owners of Repare Therapeutics Inc. - Common shares, no par value (RPTX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Shay Capital LLC | 6.7% | $7,462,367 | 2,870,141 | Shay Capital LLC | 20 Jan 2026 | |||
| ARK Investment Management LLC | 4.7% | $2,199,996 | 1,999,996 | ARK Investment Management LLC | 31 Dec 2024 | |||
| MPM BioVentures 2014, L.P. | 4.6% | -10% | $2,135,366 | -$228,990 | 1,941,242 | -9.7% | ANSBERT GADICKE | 31 Jan 2025 |
As of 31 Dec 2025, 45 institutional investors reported holding 25,162,567 shares of Repare Therapeutics Inc. - Common shares, no par value (RPTX). This represents 59% of the company’s total 42,837,925 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Repare Therapeutics Inc. - Common shares, no par value (RPTX) together control 58% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BVF INC/IL | 24% | 10,333,600 | 0% | 0.9% | $26,867,360 |
| Blue Owl Capital Holdings LP | 8% | 3,443,659 | 0% | 2.8% | $8,953,513 |
| ORBIMED ADVISORS LLC | 7.8% | 3,322,488 | 0% | 0.18% | $8,638,469 |
| Redmile Group, LLC | 3.7% | 1,586,174 | 0% | 0.3% | $4,124,052 |
| Rangeley Capital, LLC | 3% | 1,287,829 | +99% | 2.9% | $3,348,355 |
| MARSHALL WACE, LLP | 2.6% | 1,115,744 | 0% | $2,900,935 | |
| RENAISSANCE TECHNOLOGIES LLC | 2.3% | 981,360 | +36% | 0% | $2,551,536 |
| ACADIAN ASSET MANAGEMENT LLC | 1.4% | 618,672 | +8.9% | 0% | $1,606,000 |
| TWO SIGMA INVESTMENTS, LP | 0.78% | 333,694 | +2943% | 0% | $867,604 |
| JANE STREET GROUP, LLC | 0.65% | 278,304 | 0% | $723,590 | |
| Yakira Capital Management, Inc. | 0.62% | 266,601 | 0.23% | $693,162 | |
| NORTHERN TRUST CORP | 0.61% | 260,311 | -0.72% | 0% | $676,809 |
| CITADEL ADVISORS LLC | 0.56% | 238,912 | -66% | 0% | $621,171 |
| BlackRock, Inc. | 0.34% | 144,219 | -1.6% | 0% | $374,969 |
| Militia Capital Partners, LP | 0.28% | 119,176 | 0% | 0.12% | $309,857 |
| EQUITEC PROPRIETARY MARKETS, LLC | 0.28% | 118,375 | 1.5% | $307,775 | |
| XTX Topco Ltd | 0.27% | 116,933 | +146% | 0.01% | $304,026 |
| Walleye Capital LLC | 0.25% | 106,683 | 0% | $277,376 | |
| BANK OF MONTREAL /CAN/ | 0.24% | 104,919 | 0% | 0% | $272,789 |
| TWO SIGMA ADVISERS, LP | 0.13% | 54,200 | +96% | 0% | $140,920 |
| Point72 Asset Management, L.P. | 0.12% | 51,252 | 0% | $133,255 | |
| HRT FINANCIAL LP | 0.1% | 42,301 | 0% | $109,000 | |
| Quinn Opportunity Partners LLC | 0.09% | 40,000 | 0% | 0% | $104,000 |
| FNY Investment Advisers, LLC | 0.08% | 35,000 | 0.03% | $91,000 | |
| NewEdge Wealth, LLC | 0.08% | 32,959 | 0% | 0% | $85,694 |
Institutional Holders of Repare Therapeutics Inc. - Common shares, no par value (RPTX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 0 | $0 | -$94,255 | $2.59 | 0 |
| 2025 Q4 | 25,162,567 | $65,418,419 | +$649,419 | $2.60 | 45 |
| 2025 Q3 | 27,272,759 | $47,994,480 | -$585,720 | $1.76 | 44 |
| 2025 Q2 | 27,751,924 | $38,574,670 | -$1,382,414 | $1.39 | 49 |
| 2025 Q1 | 29,510,013 | $29,086,692 | -$1,273,490 | $0.99 | 49 |
| 2024 Q4 | 30,627,189 | $40,115,894 | -$3,245,437 | $1.31 | 53 |
| 2024 Q3 | 32,384,039 | $111,394,012 | -$4,678,067 | $3.44 | 56 |
| 2024 Q2 | 33,787,071 | $111,563,077 | -$7,679,698 | $3.30 | 60 |
| 2024 Q1 | 35,509,240 | $167,234,827 | -$6,368,867 | $4.71 | 70 |
| 2023 Q4 | 36,516,609 | $266,618,743 | +$7,114,924 | $7.30 | 69 |
| 2023 Q3 | 36,251,577 | $437,732,348 | +$5,862,256 | $12.08 | 75 |
| 2023 Q2 | 35,816,579 | $379,155,366 | +$27,699,133 | $10.58 | 77 |
| 2023 Q1 | 33,203,752 | $326,704,500 | -$3,869,255 | $9.84 | 77 |
| 2022 Q4 | 33,439,349 | $491,913,773 | +$9,270,562 | $14.71 | 81 |
| 2022 Q3 | 32,825,390 | $398,104,252 | -$27,705,169 | $12.13 | 68 |
| 2022 Q2 | 33,241,732 | $451,682,656 | +$10,057,776 | $13.99 | 71 |
| 2022 Q1 | 32,606,123 | $464,339,399 | -$15,992,556 | $14.24 | 61 |
| 2021 Q4 | 32,686,703 | $689,483,446 | +$73,866,430 | $21.09 | 65 |
| 2021 Q3 | 26,958,565 | $707,727,594 | +$8,752,319 | $26.24 | 66 |
| 2021 Q2 | 26,541,561 | $828,248,052 | +$17,346,878 | $31.18 | 61 |
| 2021 Q1 | 25,991,734 | $797,739,395 | +$23,245,092 | $30.69 | 64 |
| 2020 Q4 | 27,148,766 | $931,197,865 | +$31,433,436 | $34.30 | 61 |
| 2020 Q3 | 23,874,907 | $734,608,729 | +$25,936,109 | $30.77 | 37 |
| 2020 Q2 | 22,517,975 | $698,109,449 | +$698,106,449 | $31.02 | 47 |
| 2020 Q1 | 100 | $3,000 | $30.00 | 1 | |
| 2019 Q4 | 100 | $3,000 | $30.00 | 1 | |
| 2019 Q3 | 100 | $3,000 | $30.00 | 1 | |
| 2019 Q2 | 100 | $3,000 | $30.00 | 1 | |
| 2019 Q1 | 100 | $3,000 | $30.00 | 1 |